CryoCor (CRYO) had revenue of $540,000 last year, and a loss of over $15 million. It did not do much better in 2004 or 2005. But, as of this morning, the company sports a market cap of $81 million.
Nice work, if you can find it.
CryoCor’s shares are up on a deal with Boston Scientific (BSX). The two companies "are collaborating on the development of cryoablation, or extreme cold, to treat irregular heartbeat, or, cardiac arrhythmias," according to The Associated Press. Of course, the company’s quote the largest possible numbers to show the potential of the project: "About 6 million patients have the affliction worldwide, and $9 billion is spent annually in the U.S. to treat it, the companies estimated."
Of course, the device has not gone on the market yet, but CryoCor’s shares have gone from $2.50 to $6.65 in two days.
Nice work, if you can find it.
Douglas A. McIntyre can be reached at [email protected]
Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
